Melbourne-based biotechnology company Percheron Therapeutics (ASX: PER) has appointed highly experienced drug development physician Cathryn Clary as Chief Medical Advisor.
After completing her medical training, Dr Clary spent 12 years working with Pfizer, Inc in New York, NY, where she rose to the position of Senior Vice President, US Medical. She went on to hold senior roles with Ipsen Biopharmaceuticals, Inc, and with Novartis AG.
More recently, she has served as a consultant to emerging biotechnology companies, including a two-year engagement as Consulting Chief Medical Officer at Solid Biosciences, where she oversaw that company’s gene therapy program in Duchenne muscular dystrophy.
Dr Clary holds a Bachelor of Arts degree (cum laude) from Bryn Mawr College, a Medical Doctorate from the University of Missouri-Columbia, and a Master of Business Administration from the University of Delaware. She is based in New Jersey.
“We are thrilled to have an industry veteran like Cathryn join the Percheron team,” CEO, Dr James Garner, said.
“With recruitment to our phase IIb trial now complete, the team is turning its attention to next steps, including potential engagement with regulatory agencies such as FDA. Cathryn’s wealth of experience, including her impressive track record in Duchenne muscular dystrophy, will be an enormous asset for the company as we prepare for the next chapter in the development of ATL1102. In addition, Cathryn’s extensive networks among clinicians and patient advocacy in the United States will be very helpful as we work to establish ATL1102 as one of the most exciting late-clinical-stage prospects in this challenging disease area.”
Dr Clary will initially join the team in a part-time consulting role, with the opportunity to expand her position as momentum grows in the ATL1102 programme.
“I am delighted to join the Percheron team,” Dr Clary said. “Having previously worked first-hand in the Duchenne field, I am acutely aware of the need for new therapies in this disease. I am excited by the potential ATL1102 has shown to date, and I look forward to working with the team to help ensure its success. The next six to twelve months will no doubt be a transformative period for Percheron.”
